The Role of Genetic Testing in Pediatric Expressive Language Delay: Evidence from the National Brain Gene Registry
Genes · 2026
DOI: 10.3390/genes17010061 ↗Kurz gefasst
Fachartikel in der Zeitschrift Genes, 2026. Verfasst von Shivani Waghmare und 4 weiteren Autor:innen. Beteiligte Einrichtung: Howard University College of Medicine, Washington, DC 20001, USA. Hauptthemen laut MEDLINE: Genetic Testing, Language Development Disorders. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH NCATS, NIH National Human Genome Research Institute.
Abstract (Originalsprache)
Background/Objectives: Speech and language delay (SLD) is one of the most prevalent developmental conditions in childhood, with post-pandemic data indicating a notable increase in identified cases. Within this group, expressive language disorder (ELD) frequently appears alongside neurodevelopmental disorders such as autism spectrum disorder (ASD), epilepsy, and intellectual disability. Although awareness of ELD has grown, the role of genetic testing in its evaluation remains unclear, as such testing is not routinely pursued for isolated expressive language concerns. This gap highlights the need to better define the diagnostic value of genetic analysis and to examine the interval between an ELD diagnosis and the return of genetic testing results.
Methods
This study investigated genetic contributions to ELD using the National Brain Gene Registry (BGR), a multisite database of rare neurodevelopmental disorders. Participants with ICD-10 code F80.1 were identified through electronic health records; demographic data, comorbidities, genetic variants, inheritance patterns, age at diagnosis, and timing of interventions were analyzed.
Results
Of 687 BGR participants, 32 (4.7%) had documented ELD. The cohort, aged 3–19 years, presented with common comorbidities like developmental delays, ASD, epilepsy, and hypotonia. Across 42 genes, 49 unique variants were identified: 26 pathogenic or likely pathogenic, 22 variants of uncertain significance, and one benign variant. Seventeen variants were de novo, and 10 participants carried multiple variants. Most children (80%) received an expressive language diagnosis prior to genetic testing, with reports returned an average of 1.5 years following the diagnosis.
Conclusions
Overall, children with ELD commonly carry genetic variants and neurodevelopmental comorbidities, yet genetic testing is typically pursued well after diagnosis and does not currently alter early management. These findings underscore the need for clearer, evidence-based guidelines to define when genetic testing adds diagnostic or prognostic value in the evaluation of ELD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Howard University College of Medicine, Washington, DC 20001, USA.
- Children's National Medical Center, Washington, DC 20010, USA.
- St. Jude's Children's Research Hospital, Memphis, TN 38105-3678, USA.
ORCID-Profile: Alexa M Taylor, Ana Moreno Chaza
Förderung
- NIH NCATS
- NIH National Human Genome Research Institute
Zitieren
APA
Waghmare, S., Taylor, A. M., Bouska, C., Moreno Chaza, A., & Gropman, A. (2026). The Role of Genetic Testing in Pediatric Expressive Language Delay: Evidence from the National Brain Gene Registry. Genes. https://doi.org/10.3390/genes17010061
Vancouver
Waghmare S, Taylor AM, Bouska C, Moreno Chaza A, Gropman A. The Role of Genetic Testing in Pediatric Expressive Language Delay: Evidence from the National Brain Gene Registry. Genes. 2026. doi:10.3390/genes17010061
BibTeX
@article{Waghmare2026,
author = {Waghmare, Shivani and Taylor, Alexa M and Bouska, Cecilia and Moreno Chaza, Ana and Gropman, Andrea},
title = {The Role of Genetic Testing in Pediatric Expressive Language Delay: Evidence from the National Brain Gene Registry},
journal = {Genes},
year = {2026},
doi = {10.3390/genes17010061}
}
EUVIMED